Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
about
Mechanisms of Nuclear Export in Cancer and Resistance to ChemotherapyChaetocin induces apoptosis in human melanoma cells through the generation of reactive oxygen species and the intrinsic mitochondrial pathway, and exerts its anti-tumor activity in vivoNucleo-cytoplasmic transport as a therapeutic target of cancerDeciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compoundsKPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic CancerPreclinical activity of selinexor, an inhibitor of XPO1, in sarcomaThe Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.
P2860
Q26764837-49BFF7AF-A367-4860-8418-AEFCA448697FQ33574636-CEE0D9A3-7171-47A1-92DD-EE274C9D6C26Q34452108-5DE81B08-A28F-453B-BBF2-0C35E1259C2CQ35843010-8D08D088-6A98-4B01-9277-ABB009A29960Q35856215-8B647F61-2989-4308-8CE1-64463C4C56EAQ36078792-A6098151-B7B1-4D84-A1D7-A8EE35A4F12AQ37086082-F962822F-E2B8-4F62-9A6D-87A092D9E34FQ38718460-2175526B-9DC8-4227-A5C5-E1C93988573EQ38733117-EF29A001-BB82-4DF9-8DA4-F5E6EA8A55B1Q38878268-CFD31226-58D4-4E2E-B4AB-7C01422FFB11Q38881093-FD6F4A78-F783-4B20-994E-447C015FF026Q41412563-E73FCF19-CF9F-485C-942E-320B65765E7EQ43907188-61E538C3-020B-4C9B-8AB4-1859758F47D3Q51157837-32E14B71-B3C3-41F1-803A-983DCF1477D4
P2860
Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Novel small molecule XPO1/CRM1 ...... tosis in human melanoma cells.
@ast
Novel small molecule XPO1/CRM1 ...... tosis in human melanoma cells.
@en
type
label
Novel small molecule XPO1/CRM1 ...... tosis in human melanoma cells.
@ast
Novel small molecule XPO1/CRM1 ...... tosis in human melanoma cells.
@en
prefLabel
Novel small molecule XPO1/CRM1 ...... tosis in human melanoma cells.
@ast
Novel small molecule XPO1/CRM1 ...... tosis in human melanoma cells.
@en
P2093
P2860
P1433
P1476
Novel small molecule XPO1/CRM1 ...... tosis in human melanoma cells.
@en
P2093
Gregory B Lesinski
Gregory S Young
Jean-Richard Saint-Martin
Jennifer Yang
Kari Kendra
Krista La Perle
Matthew A Bill
Michael Kauffman
Sharon Shacham
Trinayan Kashyap
P2860
P304
P356
10.1371/JOURNAL.PONE.0102983
P407
P577
2014-07-24T00:00:00Z